Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysis.
Williamson J, Fadlullah MZH, Kovacsovics-Bankowski M, Gibson B, Swami U, Erickson-Wayman A, Jamison D, Sageser D, Jeter J, Bowles T, Cannon DM, Haaland B, Schroeder JD, Nix D, Atkinson A, Hyngstrom J, McPherson J, Tan AC, Hu-Lieskovan S.
Williamson J, et al. Among authors: swami u.
Res Sq [Preprint]. 2023 Jun 1:rs.3.rs-2997157. doi: 10.21203/rs.3.rs-2997157/v1.
Res Sq. 2023.
PMID: 37398360
Free PMC article.
Preprint.